Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y1RN
|
|||
| Former ID |
DIB005903
|
|||
| Drug Name |
AC-1204
|
|||
| Synonyms |
isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1], [2] | |
| Pancreatic cancer [ICD-11: 2C10] | Phase 2/3 | [3] | ||
| Company |
Accera
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H10ClN
|
|||
| Canonical SMILES |
C1C2=CC=CC=C2CN1.Cl
|
|||
| InChI |
1S/C8H9N.ClH/c1-2-4-8-6-9-5-7(8)3-1;/h1-4,9H,5-6H2;1H
|
|||
| InChIKey |
NOVIRODZMIZUPA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 32372-82-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
30277308, 49832408, 53893291, 85177443, 91749473, 92719077, 117443998, 117669042, 125002095, 125413719, 126577422, 126607462, 126628347, 126648088, 126670322, 126735255, 131269827, 131389485, 135571766, 135718030, 136378237, 137292783, 151984168, 160658633, 160794839, 162156092, 162192936, 162759750, 163808363, 164217153, 164327049, 164832362, 164963411, 165239383, 172440319, 173131223, 174474810, 185979762, 196110582, 204416993, 223248385, 223373046, 223667787, 223741180, 230604663, 249721298, 249772420, 249781535, 249816038, 249833395
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01741194) AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.